Foghorn Therapeutics(FHTX) - 2023 Q3 - Quarterly Report

For the three and nine months ended September 30, 2023 and 2022, there were no transfers between Level 1, Level 2 and Level 3. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________ _____________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR For the transition period from __________________ to __________________ Foghorn Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) _____________ ...